CurrentUnitedHealthcarePolicy CS098NM.C

Sleep Studies Nm Cs

UnitedHealthcare medical policy (New Mexico only) defining medical necessity criteria for home sleep apnea testing (HSAT), attended full-channel polysomnography (PSG), daytime sleep studies (MSLT, MWT), PAP titration, repeat testing, and exclusions such as actigraphy and certain PSG indications.

Policy Summary

PayerUnitedHealthcare

PolicySleep Studies Nm Cs

Policy CodePolicy CS098NM.C

Change TypeMaterial revisions and additions

Effective DateFeb 1, 2026

Next Review Date

Key ActionProceed to attended full-channel polysomnography rather than repeating HSAT after a single negative, inconclusive, or technically inadequate HSAT and ensure medical records document history, exam, and pertinent test results to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Added notation that performing a repeat HSAT is not recommended when an initial HSAT is negative, inconclusive, or technically inadequate; recommend attended PSG after a single non-diagnostic HSAT.

Revised coverage criteria for attended full-channel polysomnography for suspected OSA to require prior HSAT results be within the past 12 months when negative, indeterminate, or technically inadequate.

Replaced MSLT language to state MSLT is medically necessary for evaluating suspected narcolepsy when other causes of excessive sleepiness have been excluded by appropriate clinical assessment.

Clarified repeat attended PSG and repeat PAP titration are medically necessary for individuals with persistent/new symptoms despite documented treatment and for those with clinically significant weight change (≥ 10%) or changes in cardiovascular disease since the last study.

Added language about medical records documentation requirements and that documentation may be required to assess clinical criteria for coverage.

Updated Clinical Evidence and References sections to the most current information.

Updated Clinical Evidence and References sections to reflect the most current information.

Clinical Evidence and References sections updated to reflect the most current information.

Archived previous policy version CS098NM.B referenced.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleStudy types covered with criteria (HSAT, PSG, MSLT, MWT, PAP titration, repeat testing)

ActigraphyActigraphy coverage status

ABP >=21ABP members age >=21 excluded

New MexicoGeographic scope

1Material clinical changes in this revision

≥10%Weight change threshold for repeat testing

Coverage Summary

This UnitedHealthcare policy (New Mexico only) defines medical necessity criteria for sleep studies including Home Sleep Apnea Testing (HSAT), attended full‑channel polysomnography (PSG, attended laboratory studies), daytime studies (MSLT, MWT), attended PAP titration (split‑night or full‑night), and repeat testing, and lists exclusions (e.g., actigraphy and select PSG indications). The geographic scope is explicitly New Mexico only. The policy applies adult HSAT indications and distinguishes children/adolescents (<18 years) as a group for whom attended PSG is indicated. Overall coverage stance is mixed: HSAT is medically necessary for appropriately selected adults, attended PSG and other studies are medically necessary under specified clinical circumstances, and several tests/studies are listed as not medically necessary.

Key thresholds & quick facts

Geographic scopeNew Mexico only

HSAT minimum monitoring timeMinimum 4 hours recording with nasal pressure, chest & abdominal respiratory inductance plethysmography, and oximetry

Repeat HSAT after non-diagnostic resultNot recommended after a single negative, inconclusive, or technically inadequate HSAT; proceed to attended PSG

FEV1 threshold prohibiting HSATFEV1 % predicted < 60 (significant chronic pulmonary disease)

Clinically significant weight change for repeat testing≥ 10% weight loss or gain

OSA severity (AHI/RDI) thresholdsMild: ≥5 and <15; Moderate: ≥15 and ≤30; Severe: >30 events/hour

ABP exclusionSleep studies not covered for Alternative Benefit Package members age ≥21

Medical-Necessity Criteria

Home Sleep Apnea Testing (HSAT) - Medically Necessary

HSAT using a portable monitor is medically necessary for evaluating adults with suspected OSA when criteria below are met:

Individual is an adult with suspected Obstructive Sleep Apnea (OSA).

Attended Full-Channel Polysomnography (PSG) - Medically Necessary for Suspected OSA

Attended PSG is medically necessary for evaluating individuals with suspected OSA when ANY of the following are met:

Results of previous HSAT within the past 12 months are negative, indeterminate, or technically inadequate to make a diagnosis of OSA.

Individual is a child or adolescent (less than 18 years of age).

Individual has one or more comorbid medical conditions that prohibit the use of HSAT

Provider Actions & Documentation

Documentation Required

Medical record documentation required

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. This documentation must include a relevant history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation supporting medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request. Providers should use clinical judgment and may incorporate validated third-party assessment tools (for example, the Epworth Sleepiness Scale) as appropriate to support the evaluation and decision-making process.

History, physical exam, and pertinent diagnostic test results must be documented
Documentation must be legible, maintained in the medical record, and available upon request
Use clinical judgment and consider validated third-party tools (e.g., Epworth Sleepiness Scale) as appropriate

Prior Authorization

Policy applies to New Mexico members

This policy applies to New Mexico members. Verify state-specific regulatory requirements, member eligibility, and benefit plan provisions prior to ordering or performing testing.

Coding

CPT/HCPCS Codes Listed (reference only)mixed

95782	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95783	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist.
95800	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time.
95801	Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone).
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).
95805	Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness.
95806	Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (e.g., thoracoabdominal movement).
95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.

1–10 of 14

1/2

Background & Evidence

Background: Obstructive Sleep Apnea (OSA) and other sleep disorders may be evaluated either at home or in a sleep laboratory. HSAT (unattended) uses portable monitors to record respiratory parameters (breathing/airflow, heart rate, oxygen saturation) and is intended to assess OSA without determination of sleep stage; an adequate HSAT records a minimum of 4 hours and includes sensors such as nasal pressure, chest and abdominal effort, and oximetry. In contrast, attended polysomnography (PSG) is a laboratory‑based, technologist‑attended, full‑channel study (Type 1) that records multiple physiologic signals including EEG, EOG, EMG, respiratory effort, airflow, oximetry, movement and cardiac activity.

Device classification and diagnostic criteria: The AASM classifies devices as Type 1 (full attended PSG, ≥7 channels), Type 2 (full unattended PSG, ≥7 channels), Type 3 (limited channel devices, typically 4–7 channels), and Type 4 (1–2 channels, often oximetry). The AASM diagnostic thresholds define OSA severity by AHI or RDI as mild ≥5 and <15 events/hour, moderate ≥15 and ≤30 events/hour, and severe >30 events/hour. AASM guidance supports using HSAT with a technically adequate device in uncomplicated adults at increased risk of moderate-to-severe OSA, and recommends that if a single HSAT is negative, inconclusive, or technically inadequate, PSG should be performed rather than repeating HSAT.

Citation	Key Point
Kapur et al., 2017
If a single HSAT is negative, inconclusive, or technically inadequate, PSG is strongly recommended rather than repeating HSAT; adequate HSAT defined as minimum 4 hours with nasal pressure, chest and abdominal effort, and oximetry.
AASM diagnostic thresholds
OSA severity defined by AHI/RDI: Mild ≥5 and <15; Moderate ≥15 and ≤30; Severe >30 events/hour; diagnostic thresholds described for when PSG/HSAT confirm OSA.
PAP-Nap pilot results (Krakow et al., 2008)
Pilot PAP-Nap: higher completion of overnight titrations (90% vs 63%), higher prescription fills (85% vs 35%), and higher regular PAP use (67% vs 23%) versus historical controls; authors call for larger prospective studies.
AASM guidance (Kapur et al., 2017)
AASM recommends that if a single HSAT is negative, inconclusive, or technically inadequate, PSG be performed for diagnosis of OSA (strong recommendation); single-night HSAT generally adequate in appropriate populations but repeat HSAT not recommended after a non-diagnostic result.
AASM actigraphy recommendations (Smith et al., 2018b)
AASM suggests clinicians may use actigraphy for estimating sleep parameters in insomnia and circadian rhythm disorders (conditional) and recommends not using actigraphy in place of EMG for diagnosing periodic limb movement disorder (strong).

Definitions (term = concise definition)

HSATUnattended diagnostic study for OSA without sleep staging; adequate HSAT = minimum 4 hours and sensors: nasal pressure, chest & abdominal effort, oximetry

Medicare / Regulatory Determinations

Name	Details
FDA 510(k) clearances
Systems to record/analyze PSG information cleared under 510(k) (product code OLV); HSAT devices cleared under 510(k) (product code MNR). This section is informational only: FDA clearance alone is not a basis for coverage.

Revision History

02/01/2026addedLatest

Added notation that performing a repeat HSAT is not recommended when an initial HSAT is negative, inconclusive, or technically inadequate; recommend attended PSG after a single non-diagnostic HSAT. (material)

02/01/2026revised

02/01/2026

Operational Notes & Documentation Expectations

Medical Records Documentation Used for Reviews; Supporting Documentation Requirements

Documentation expectations to support medical necessity:

Benefit coverage is determined by federal, state, contractual requirements, and applicable laws that may require coverage for a specific service

Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services

Documentation includes but is not limited to relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures

Policy Summary

PayerUnitedHealthcare

PolicySleep Studies Nm Cs

Policy CodePolicy CS098NM.C

Change TypeMaterial revisions and additions

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

Significant Chronic Pulmonary Disease defined by a forced expiratory volume (FEV1) % predicted of < 60.FEV1% < 60

Progressive neuromuscular disease or neurodegenerative disorder (examples include Parkinson's disease, myotonic dystrophy, amyotrophic lateral sclerosis, multiple sclerosis with associated pulmonary disease, history of stroke with persistent neurological sequelae).

Moderate to severe heart failure: New York Heart Association (NYHA) class III or IV or left ventricular ejection fraction ≤ 40.NYHA III/IV or LVEF ≤ 40

Body mass index (BMI) > 50.BMI > 50

Obesity Hypoventilation Syndrome.

Documented ongoing epileptic seizures in the presence of symptoms of sleep disorder.

Chronic opiate medication use (> 3 months).> 3 months

Attended PSG - Medically Necessary for Other Conditions

Attended PSG is medically necessary following appropriate clinical assessment when OSA has been excluded/treated or symptoms suggest the following conditions:

Periodic Limb Movement Disorder (PLMD) (not leg movements associated with another disorder such as sleep disordered breathing).

Restless Legs Syndrome (RLS)/Willis-Ekbom Disease that has not responded to treatment.

Parasomnia with documented disruptive, violent, or potentially injurious sleep behavior suspicious of Rapid Eye Movement Sleep Behavior Disorder (RBD).

Narcolepsy, once other causes of Excessive Sleepiness have been ruled out by appropriate clinical assessment.

Central Sleep Apnea.

Implantable Hypoglossal Nerve Stimulator - Pre-implantation/Calibration Testing

Attended PSG is medically necessary to rule out Central Sleep Apnea prior to implantation and/or calibration when device is indicated.

PSG performed prior to implantation/calibration to rule out Central Sleep Apnea.

Refer to Obstructive and Central Sleep Apnea Treatment policy for device indications.

Studies Not Medically Necessary

The following are not medically necessary due to insufficient evidence:

Attended full-channel PSG for evaluating Circadian Rhythm Disorders.

Attended full-channel PSG for evaluating Depression.

Attended full-channel PSG for evaluating Insomnia.

Actigraphy for any sleep disorders.

Daytime Sleep Studies - MSLT and MWT

Medically necessary criteria for daytime testing:

MSLT is medically necessary for evaluating suspected Narcolepsy or idiopathic Hypersomnia when other causes of Excessive Sleepiness have been excluded by appropriate clinical assessment.

MWT medically necessary criteria (adults only): An adult who is unable to stay awake, resulting in a safety issue.

MWT medically necessary criteria (adults only): Assessing response to treatment in adults with sleep disorders.

MWT is unproven and not medically necessary in children and adolescents less than 18 years of age.

Abbreviated daytime sleep studies (e.g., PAP-Nap) are not medically necessary due to insufficient evidence of efficacy.

Attended PAP Titration - Medically Necessary

When individual meets attended PSG criteria, the following titration studies are medically necessary:

A split-night sleep study performed in a healthcare facility or laboratory setting for diagnosis and PAP titration.

A full night study for PAP titration when a split-night study is inadequate or not feasible and the individual has a confirmed diagnosis of OSA.

Attended Repeat Testing - Medically Necessary

Repeat attended PSG and repeat PAP titration are medically necessary in the following circumstances:

Individuals with persistent, recurrent or new symptoms despite documented appropriate current treatment or PAP therapy (examples: equipment failure, improper mask fit, pressure leaks, unsuccessful titration, inadequate pressure) and medical problems (including nasal congestion) have been addressed and appropriately managed.

Individuals who have experienced a clinically significant weight loss or gain (≥ 10%) or changes in cardiovascular disease since the last study.>= 10% weight change

Repeat Testing for Oral Appliance Adjustments

Operational note:

Repeat testing and repositioning/adjustments for oral sleep appliances can be done in the home unless the individual meets criteria for an attended sleep study.

Home Sleep Apnea Testing (HSAT) — repeat testing recommendation

Policy notation regarding repeat HSAT after an initial non-diagnostic result:

Performing a repeat HSAT is not recommended when an initial HSAT is negative, inconclusive, or technically inadequate, due to the higher likelihood that a second HSAT will also be negative, inconclusive, or technically inadequate

After a single negative, inconclusive, or technically inadequate HSAT result, performance of attended full-channel polysomnography is strongly recommended

Attended Full-Channel Polysomnography (PSG) — suspected OSA

Revised coverage criteria for attended PSG in evaluating suspected OSA:

Attended full-channel PSG is indicated when results of previous HSAT (within the past 12 months) are negative, indeterminate, or technically inadequate to make a diagnosis of OSAHSAT within 12 months

Daytime Sleep Studies — MSLT

Revised MSLT coverage language:

Multiple Sleep Latency Testing (MSLT) is medically necessary for evaluating suspected narcolepsy when other causes of excessive sleepiness have been excluded by appropriate clinical assessment

Attended Repeat Testing (PSG / PAP titration)

Criteria for repeat attended studies and titration:

Repeat attended full-channel polysomnography and repeat Positive Airway Pressure (PAP) titration are medically necessary for individuals who have persistent or new symptoms despite documented appropriate current treatment or PAP therapy

Repeat attended full-channel polysomnography and repeat PAP titration are medically necessary for individuals who have experienced a clinically significant weight loss or gain (≥ 10%) since the last study>= 10% weight change

Repeat attended full-channel polysomnography and repeat PAP titration are medically necessary for individuals who have changes in cardiovascular disease since the last study

Denial Risk

ABP members age 21 and over exclusion

Sleep studies are not covered for Alternative Benefit Package (ABP) members age 21 and over. Confirm ABP status and age before authorizing or performing testing to avoid coverage denials.

Documentation Required

HSAT adequacy and repeat testing guidance

Repeat HSAT is not recommended after a single negative, inconclusive, or technically inadequate HSAT because of the low likelihood that a second test will be diagnostic. When an initial HSAT is non-diagnostic, attended full-channel polysomnography (PSG) is strongly recommended.

Prior Authorization

Perform attended PSG after non-diagnostic HSAT

If an initial HSAT is negative, inconclusive, or technically inadequate, proceed to an attended full-channel PSG rather than repeating HSAT. Consider prior authorization/workflow implications for scheduling attended PSG when HSAT is non-diagnostic.

Prior Authorization

Repeat PSG / PAP titration criteria

Repeat attended PSG and repeat PAP titration should be obtained only for individuals with persistent, recurrent, or new symptoms despite documented appropriate current treatment or PAP therapy, or for individuals who have experienced a clinically significant weight change (≥ 10%) or changes in cardiovascular disease since the prior study.

Persistent, recurrent, or new symptoms despite documented appropriate treatment
Clinically significant weight change (≥ 10%) since prior study
Changes in cardiovascular disease since prior study

Documentation Required

Follow federal/state/contractual requirements

Benefit coverage is determined by federal, state, or contractual requirements and applicable laws. Providers must reference the member's applicable benefit plan for specific coverage rules; this policy is informational and does not replace plan language.

AHI (Apnea Hypopnea Index)

Number of apneas plus hypopneas per hour of sleep; used to classify OSA severity

MWT (Maintenance of Wakefulness Test)Daytime test measuring ability to stay awake in nonstimulating conditions; medically necessary in adults for safety or treatment assessment

PSG (Polysomnography)Full-channel attended laboratory sleep study recording multiple physiologic channels (brain activity, eye movements, breathing, oximetry, etc.)

MSLT (Multiple Sleep Latency Test)Daytime study measuring physiological sleep tendency; medically necessary for suspected narcolepsy after other causes excluded

Replaced MSLT language to state MSLT is medically necessary for evaluating suspected narcolepsy when other causes of excessive sleepiness have been excluded by appropriate clinical assessment. (material)

02/01/2026revised

02/01/2026added

Added language about medical records documentation requirements and that documentation may be required to assess clinical criteria for coverage. (material)

updated

Updated Clinical Evidence and References sections to the most current information. (non-material)

clarified

Policy history notes repeatedly indicate updates to Clinical Evidence and References; no specific clinical coverage criteria changes are present in this excerpt. (non-material)

clarified

Multiple entries in the revision history note updates to Clinical Evidence, References, and Supporting Information. (non-material)

archived

Archived previous policy version CS098NM.B referenced. (non-material)

Documentation supporting medical necessity should be legible, maintained in the patient's medical record, and made available upon request